Experience

Charlie Kim

    • Uber Technologies $8.1 Billion IPO 


    • Sweetgreen – $418.6 Million IPO 


    • 10X Genomics – $449 Million IPO  


    • Lyell Immunopharma – $425 Million IPO 


    • Sana Biotechnology - $676 million IPO 


    • ORIC Pharmaceuticals - $138 Million IPO 


    • Zentalis Pharmaceuticals - $190 Million IPO 


    • Fangdd $78 Million – IPO 


    • Vir Biotechnology - $143 Million IPO 


    • EHang Holdings - $40 Million IPO 


    • Medallia - $374 Million IPO 


    • Livongo Health - $409 Million IPO 


    • Health Catalyst - $209 Million IPO 


    • Allogene Therapeutics – $372.6 Million IPO 


    • Gossamer Bio – $317 Million IPO 


    • ShockWave Medical – $111 Million IPO 


    • Jazz Pharmaceuticals in $314.4 million Offering 


    • Cooley's Capital Markets Leadership Continues through 1H 2014 


    • Receptos, Inc. Initial Public Offering 


    • Crinetics Pharmaceuticals – $117 Million IPO 


    • Eidos Therapeutics – $122 Million IPO 


    • Neon Therapeutics – $100 Million IPO 


    • Tricida – $256 Million IPO 


    • Aridis – $26 Million IPO 


    • Gritstone Oncology – $100 Million IPO 


    • Aerohive Networks $75 Million IPO 


    • TriVascular Initial Public Offering 


    • Vital Therapies Initial Public Offering 


    • Kite Pharma $146 Million Initial Public Offering 


    • Minerva Neurosciences $32.7 Million IPO 


    • Immune Design $63 Million Initial Public Offering 


    • Otonomy $100 Million IPO 


    • Demira Prices $125 Million IPO 


    • Xenon Pharmaceuticals Completes Initial Public Offering 


    • HealthEquity $146 Million Initial Public Offering 


    • Ascendis Pharma closes $124 million IPO 


    • TRACON Pharmaceuticals Completes Initial Public Offering 


    • Cidara Completes Initial Public Offering  


    • Apigee Completes Initial Public Offering 


    • Invitae Completes $117 Million Initial Public Offering  


    • Advaxis – $30 Million Registered Direct Offering 


    • Cooley Advises Underwriters on Vital Therapies IPO 


    • MINDBODY Completes $100 Million IPO 


    • Ooma Prices $65 Million IPO 


    • NantKwest IPO - $238 Million IPO 


    • ProNAi Therapeutics - $158 Million IPO 


    • FireEye Completes 144A Private Placement of $920 Million Convertible Senior Notes 


    • Gemphire Therapeutics – $30 Million IPO 


    • Ionis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes 


    • Jazz Pharmaceuticals – $575 Million Exchangeable Senior Note Offering 


    • MINDBODY Completes $100 Million IPO 


    • NantKwest – $238 Million IPO 


    • ProNAi – $158 Million IPO 


    • Verona – $80 Million IPO 


    • Zealand Pharma – $89 Million IPO 


    • Zymeworks – $58.5 Million IPO 


    • Sutro Biopharma – $85 Million IPO 


    • Guardant Health – $273.1 Million IPO 


    • Seattle Genetics: $552 Million Follow-On 


    • Ionis Pharmaceuticals Completes Rule 144A Offering $500 Million of Convertible Senior Notes 


    • FireEye Completes 144A Private Placement of $920 Million Convertible Senior Notes 


    • Tableau Software – $292 Million IPO and Follow-On Offerings 


    • Five Prime Therapeutics IPO 


    • Amedica Initial Public Offering 


    • Castlight Health's $204 Million IPO 


    • Akero Therapeutics - $106 Million IPO 


    • IGM Biosciences – $201 Million IPO  


    • Exagen Diagnostics – $58 Million IPO  


    • Phathom Pharmaceuticals - $209 Million IPO 


    • 89bio – $98 Million IPO 


    • Insys Therapeutics IPO 


    • Reata Pharmaceuticals – $505 Million Follow-On Offering 


    • Pliant Therapeutics - $166 Million IPO 


    • The Underwriters On Guardant Health's $1.1 Billion Follow-On Offering 


    • The Underwriters On Livongo Health's $550 Million Convertible Senior Notes 


    • Applied Molecular Transport - $177 Million IPO 


    • Avidity Biosciences - $289 Million IPO 


    • Vaxcyte - $288 Million IPO 


    • Poseida Therapeutics – $224 Million IPO 


    • Acutus Medical – $183 Million IPO 


    • Athira Pharma – $204 Million IPO 


    • Inhibrx – $137 Million IPO 


    • Annexon – $251 Million IPO 


    • TiVo and Xperi to Combine in $3 Billion All-Stock Merger 


    • 4D Molecular Therapeutics - $222 million IPO 


    • AbCellera Biologics - $556 million IPO 


    • Kinnate Biopharma - $276 million IPO 


    • Arcutis – $192.5 Million Follow-On Offering 


    • Mirati – $1.0 Billion Follow-On Offering  


    • Dutch Bros – $556.8 Million IPO 


    • PROCEPT BioRobotics – $188.5 Million IPO 


    • DICE Therapeutics – $234.6 Million IPO 


    • Rani Therapeutics – $73 Million IPO 


    • Erasca – $345 Million IPO 


    • Elevation Oncology – $107 Million IPO 


    • Graphite Bio – $274 Million IPO 


    • Ambrx Biopharma – $126 Million IPO 


    • Singular Genomics Systems – $258 Million IPO 


    • Doximity – $697 Million IPO 


    • FIGS – $668 Million IPO 


    • Day One Biopharmaceuticals – $184 Million IPO 


    • Janux Therapeutics – $194 Million IPO 


    • Treace Medical Concepts – $220 Million IPO 


    • Biomea Fusion – $153 Million IPO 


    • Silverback Therapeutics– $278 Million IPO 


    • Olink Holding – $406 Million IPO 


    • Vor Biopharma – $203 Million IPO  


    • Longboard Pharmaceuticals – $80 Million IPO 


    • Angion Biomedica – $92 Million IPO 


    • Gracell Biotechnologies – $209 Million IPO  


    • Ventyx Biosciences – $174.3 Million IPO 


    • Qualtrics International – $1.15 Billion Follow-On Offering 


    • Global Blood Therapeutics – $345 Million Convertible Senior Notes Offering 


    • Route Hits $1.25 Billion Valuation With Series B Round 


    • Ascendis Pharma – $460 Million Follow-On Offering 


    • IGM Biosciences – $230 Million Follow-On Offering 


    • Ascendis Pharma – $575 Million Convertible Senior Notes Offering